Athira Pharma 

Yahoo Finance • 6 days ago

Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO

(RTTNews) - The biotech industry witnessed several key events this week, including major FDA approvals, acquisitions, pivotal clinical trial results and setbacks. • A series of FDA approvals were announced during the week, with GSK, Haloz... Full story

Yahoo Finance • 8 days ago

Sector Update: Health Care Stocks Rise Late Afternoon

Health care stocks rose late Thursday afternoon, with the NYSE Health Care Index and the State Stree PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 8 days ago

BC-Most Active Stocks

NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change urban-gro Inc. 98,786,371 0.4595 0.3802 0.3921 +0.0961 Vivakor Inc. 55,7... Full story

Yahoo Finance • 8 days ago

Investors Await Key Inflation, Employment Data as US Futures Rise Thursday Pre-Bell

US stock futures are rising in Thursday's premarket session as investors await key inflation data an PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 3 months ago

Carlton Precious Announces Filing of Notice of Intention to Sell Athena Gold Corporation Common Shares

TORONTO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Carlton Precious Inc. (TSX-V: CPI | OTCQB: CPIFF) ("Carlton Precious" or the "Company") announces that the Company has filed a notice of intention to distribute securities (Form 45-102F1) (the... Full story

Yahoo Finance • 3 months ago

Athira Pharma Announces Reverse Stock Split

BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (“Athira” or “Company”) (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodege... Full story

Yahoo Finance • 4 months ago

Athira Pharma reports positive Phase 1 results for ALS drug candidate

BOTHELL, Wash. - Athira Pharma, Inc. (NASDAQ:ATHA), a clinical-stage biotech with strong liquidity ratios and more cash than debt according to InvestingPro data, presented results from its Phase 1 clinical trial of ATH-1105 at the ALS Nexu... Full story

Yahoo Finance • 7 months ago

Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit

Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical development On-track to enable initia... Full story

Yahoo Finance • 2 years ago

Athira Pharma to Participate in Sidoti December Small Cap Investor Conference

BOTHELL, Wash., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today anno... Full story

Yahoo Finance • 2 years ago

Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND

BOTHELL, Wash., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today anno... Full story

Yahoo Finance • 2 years ago

Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton’s Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer’s Disease

BOTHELL, Wash., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, presented... Full story

Yahoo Finance • 2 years ago

Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates

Continues to report clinical and preclinical findings supporting the potential benefits of its small molecule therapeutic candidates targeting the neurotrophic HGF system as potential novel treatments for neurodegenerative diseases Expect... Full story

Yahoo Finance • 2 years ago

Athira Pharma to Participate in Jefferies London Healthcare Conference

BOTHELL, Wash., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today anno... Full story

Yahoo Finance • 2 years ago

Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

New results support the neuroprotective effects of ATH-1105 in preclinical models of ALS, as indicated by consistent reduction in plasma neurofilament light chain (NfL) levels and preservation of motor function Data presented at invitatio... Full story

Yahoo Finance • 2 years ago

Athira Pharma to Participate in Upcoming October Conferences

BOTHELL, Wash., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today ann... Full story

Yahoo Finance • 2 years ago

Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

BOTHELL, Wash., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today ann... Full story

Yahoo Finance • 2 years ago

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery.... Full story

Yahoo Finance • 2 years ago

Athira Pharma Announces Upcoming Presentations at the Alzheimer’s Association International Conference (AAIC) 2023

BOTHELL, Wash., July 06, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today anno... Full story

Yahoo Finance • 3 years ago

Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting

Oral presentation to highlight additional clinical data from Phase 2 ACT-AD trial of fosgonimeton in mild-to-moderate Alzheimer’s disease patients including improvements in measures of cognition and plasma biomarkers Oral presentation to... Full story

Yahoo Finance • 3 years ago

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2023 International Conference

BOTHELL, Wash., March 28, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today pre... Full story